ArticlePloS one2024

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.

Graham Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.